wave

Our Clinical Trials

TESARO is sponsoring several clinical research trials in ovarian cancer:

  • The PRIMA clinical research trial is being done to find out if niraparib, an investigational drug called a PARP inhibitor, can help delay the worsening of ovarian, peritoneal, or fallopian tube cancer for women who have had at least 4 cycles of front-line platinum-based therapy (i.e. carboplatin, oxaliplatin, cisplatin) and who have an HRD-positive tumor. (Potential participants will have their tumor tested first, at no cost, to see if PRIMA is a good fit for them.)
  • The QUADRA clinical research trial is being done to find out if nirapirib can help delay the worsening of ovarian, peritoneal, or fallopian tube cancer for women who have had 3 or 4 previous rounds of chemotherapy.
  • The NOVA clinical research trial is being done to determine whether niraparib can help delay progression of ovarian, peritoneal, or fallopian tube cancer for women who had a good response to previous treatment with a platinum-based chemotherapy (i.e. carboplatin, oxaliplatin, cisplatin). TESARO sincerely thanks the many women who participated in our NOVA clinical research trial.  See the October 8, 2016 press release:  http://ir.tesarobio.com/releasedetail.cfm?ReleaseID=992742   THIS TRIAL HAS REACHED ITS ENROLLMENT GOAL AND IS NO LONGER ENROLLING NEW PARTICIPANTS.